The John H. Stroger Jr. Hospital of Cook County (formerly Cook County Hospital) is a public hospital in Chicago, Illinois, United States. It is part of the Cook County Health and Hospital System, along with Provident Hospital of Cook County and several related centers, which provides public primary, specialty, and tertiary healthcare services to residents of Cook County, Illinois.Cook County Hospital was founded 1832, and became an innovative teaching hospital. In 2001-2002, it moved into new quarters adjacent to its historic Beaux-Arts complex in the Illinois Medical District and was renamed for hospital board president John Stroger Jr.
Granular cell tumors (GCTs) are rare, typically benign Schwann cell neoplasms; within the gastrointestinal (GI) tract, the esophagus is the most frequent site. Eosinophilic gastrointestinal diseases are chronic immune-mediated conditions encompassing eosinophilic esophagitis, gastroenteritis, and colitis. We describe a 49-year-old man with prior testicular seminoma, follicular thyroid carcinoma, and cutaneous GCTs who developed multifocal esophageal and rectal GCTs alongside eosinophilic esophagitis, esophagitis gastroenteritis, and esophagitis colitis, plus an incidental sigmoid neuroendocrine tumor (WHO grade 2). To our knowledge, this is the first reported case of concurrent multisegmental eosinophilic gastrointestinal diseases, multifocal GCTs, and a neuroendocrine tumors (NET), highlighting the need for vigilant endoscopic surveillance.
Obesity is a recognized risk factor for developing pelvic organ prolapse and for perioperative complications. As the population ages, an increasing number of older, obese individuals with prolapse may opt for surgical repair. This study assesses the association between obesity and short-term perioperative adverse events (AEs) in women ≥ 70 years undergoing vaginal and laparoscopic prolapse surgery. This is a secondary analysis of a retrospective cohort study of older women undergoing vaginal and laparoscopic prolapse surgery at two medical centers from 2016 to 2023. Patients were classified as nonobese (< 30 kg/m2), class 1 obese (30–34.9 kg/m2), or class 2+ obese (≥ 35 kg/m2). The primary outcome was composite AEs within 8 weeks after surgery, and secondary outcomes included major AEs and individual AEs. Of 1507 older women, 20.8
Renal Cell Carcinoma (RCC) has a metastasis rate of approximately 33%, but metastasis to the breast is extremely rare1. The common sites of metastasis include lung, bone, lymph nodes, and liver2. Here we present a case of RCC that metastasized to the breast three months after radical nephrectomy. In September 2019, a 65 year old female was diagnosed with cT2bN0M0 RCC. She was treated with Cabozantinib due to her past history of heart failure. Five months after the initial diagnosis she underwent left radical nephrectomy and left adrenal gland resection due to metastasis. This surgery resulted in negative margins and no lymph node involvement. Three months later a 1.6cm breast mass was discovered and a biopsy confirmed RCC. After it was confirmed that she had no other sites of metastasis and after multidisciplinary discussion, a lumpectomy was performed. All margins were negative apart from a focally positive margin, however fascia was removed without any evidence of muscular invasion. Although it was discussed at a multidisciplinary conference, adjuvant radiation was not started due to a lack of data to support its use in RCC. Four months later a surveillance CT revealed recurrence with right adrenal gland metastases and multiple subcentimeter nodules in the left breast. She was then started on Axitinib with pembrolizumab. After nine cycles of this immunotherapy regimen a CT found equivocal standardized uptake value (SUV) on the right adrenal metastasis and a 6th rib lytic lesion, but the breast mass did not have an elevated SUV. She underwent repeat breast biopsy which showed RCC, and she continued on her immunotherapy regimen for 2 more cycles due to the presence of other metastatic disease. She underwent repeat breast imaging which showed known masses, 2 of which had increased in size (one from 11 mm to 23 mm and one from 7 mm to 10 mm) and osseous destruction of the sixth rib which was causing increased rib pain. She underwent palliative left mastectomy and radiation therapy to the affected rib and chest wall. The final pathology showed 3 foci of metastatic clear cell carcinoma (1.8cm, 2cm, and 0.3cm) with negative margins in the breast and the patient received adjuvant radiation therapy of the left chest wall and was restarted on pembrolizumab. A later CT showed soft tissue invasion on the left chest wall. The chest wall lesion demonstrated metastatic RCC, but the pembrolizumab was stopped due to lack of response and arthritis. Three months later she presented to the ED after a fall and was found to have metastases in the left anterior frontal lobe. After brain lesion resection she was started on Everolimus. Five months later there were no new lesions seen on imaging, and the brain lesion had decreased in size. This case demonstrates a rare breast metastasis of RCC to add to the small body of case reports that describe this phenomenon. Documenting these cases is important in order to direct treatment options for future cases of RCC metastasis to the breast. Although resection of oligometastatic disease has been described, data is insufficient to indicate that it has an effect on survival. 1. Flanigan, R. C., Campbell, S. C., Clark, J. I. & Picken, M. M. Metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 4, 385-390 (2003).2. Bianchi, M. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 23, 973-980 (2012). M. G. Moulton, E. A. Marcus, J. S. Wecsler. A Rare Metastasis of Renal Cell Carcinoma to the Breast: A Case Report [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-06-10.
BACKGROUND:Alpha-fetoprotein (AFP) is the most widely used biomarker for hepatocellular carcinoma (HCC) diagnosis; however, its sensitivity is limited, especially for early-stage disease and in AFP-negative HCC cases. Pentraxin-3 (PTX3), a marker of local inflammation and angiogenesis, may outperform AFP in detection by reflecting distinct biological pathways involved in hepatocarcinogenesis. METHODS:PubMed, Embase, Web of Science, Cochrane, and ClinicalTrials.gov were searched through December 2025 following PRISMA guidelines. Eligible studies included adults with chronic liver disease evaluated for suspected or established HCC. Pooled sensitivity and specificity were calculated using the bivariate Reitsma model, and the overall diagnostic performance was assessed using. sensitivity, specificity, and diagnostic odds ratio, along with determining the area under the curve (AUC). RESULTS:Five retrospective studies involving 1179 participants, including 362 patients with HCC, met the inclusion criteria. Using the bivariate Reitsma model, the pooled sensitivity and specificity of PTX3 were 0.79 (95% CI 0.74-0.84) and 0.83 (95% CI 0.76-0.88), respectively, with an AUC of 0.876. AFP alone showed a sensitivity of 0.76 (95% CI 0.70-0.80) and specificity of 0.81 (95% CI 0.74-0.86), with an AUC of 0.849. The combined PTX3 + AFP approach had sensitivity of 0.92 (95% CI 0.89-0.94), specificity of 0.85 (95% CI 0.77-0.90), with a DOR of 65.8 and an AUC of 0.942. CONCLUSIONS:PTX3 demonstrated diagnostic performance comparable to AFP; however, the combination of PTX3 and AFP was associated with higher pooled sensitivity.
Introduction: Nausea and vomiting are common in early pregnancy and are often attributed to hyperemesis gravidarum (HG). However, with increasing cannabis use among women of reproductive age, cannabinoid hyperemesis syndrome (CHS) has emerged as an important differential diagnosis. The clinical overlap between these conditions is demonstrated in this case with the aim to bring attention to the diagnostic challenge, especially in the pediatric population. Case Report: A 15-year-old gravida 1 para 0 woman at 6 weeks’ gestation presented with persistent nausea, repeated vomiting, abdominal pain, and dehydration, without any known symptomatic relief. The patient was initially diagnosed with HG, but further history was notable for daily cannabis use for the past one year. Despite supportive management and antiemetic therapy, symptoms persisted until pregnancy termination and cessation of cannabis usage. The patient was later readmitted with similar symptoms after restarting cannabis usage. Conclusion: Cannabinoid hyperemesis syndrome closely mimics HG and may lead to diagnostic confusion during pregnancy. Detailed substance use history, awareness of CHS features, and prompt cannabis cessation are essential for appropriate management.